DR Tech Corp

DR Tech Corp's capital structure is characterized by a debt-to-equity ratio of 1.15, indicating a moderate reliance on debt financing. The company's liquidity position is mixed, with a current ratio of 2.03 but negative free cash flow of -19.7 billion KRW and operating cash flow of -20.1 billion KRW, suggesting cash generation challenges. The price-to-book ratio of 1.85 implies that the market values the company at a premium to its book value, though this is not uncommon in capital-intensive industries. Profitability metrics are concerning, with a return on equity of -31.3% and return on assets of -11.9%, both significantly below the industry median for medical equipment firms. The company reported a net loss of 24.0 billion KRW and an operating loss of 15.3 billion KRW, indicating operational inefficiencies or pricing pressures. Gross profit of 41.98 billion KRW on revenue of 116.3 billion KRW yields a gross margin of 36.1%, which is in line with industry norms but insufficient to offset operating costs. The company's revenue is concentrated in a single business segment focused on X-ray detectors and medical software, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to sector-specific risks, such as regulatory changes or supply chain disruptions. Growth prospects are muted, with no disclosed revenue growth in the latest period and a negative operating cash flow. The company's capex of -6.77 billion KRW suggests ongoing investment in production capabilities, but without a clear path to profitability, the return on these investments remains uncertain. The outlook for the current fiscal year is cautious, with no material revenue growth expected in the near term. Risk factors include liquidity constraints, as the company's cash and equivalents of 21.16 billion KRW are insufficient to cover its long-term debt of 88.42 billion KRW. The risk assessment flags a net cash position that is negative after subtracting total debt, signaling potential refinancing risks. Dilution risk is currently low, with no near-term pressure from share issuance or convertible instruments. Recent filings and transcripts have not disclosed any material events or strategic shifts. The company remains focused on its core product lines, with no indication of diversification or new market entry in the latest disclosures.